Editorial

HIV Treatment Bulletin - Vol. 8, No. 6/7, June-July 2007

This issue leads with a treatment alert relating to the European recall of nelfinavir. As we went to press, the EMEA are working with Roche to formulate a patient registry to follow patients exposed to any level of contaminated drug. Further details will be announced as soon as they are available.

We also include first reports from the XVI International Resistance Workshop that focus on the first chance to look at issue of resistance relating to integrase inhibitors.

This issue includes the last of our reports from the Retrovirus conference and a selection of studies from the PK Workshop held in April.

i-Base update

The new Guide to HIV, Pregnancy and Women’s Health is included as a supplement to this issue of HTB. For additional copies of this guide (additional bulk print copies are free to UK clinics), please order these online: http://www.i-base.info/forms/order.php?women=true.

This month other new translations of the Introduction to Combination Therapy have been produced (in Czech, Croatian, Bosnian and Macedonian) and the Treatment Training for Advocates manual has been produced in Portuguese. All these publications are available as PDF files to download from the i-Base website. i-Base have also launched an online general treatment Q&A service: http://www.i-base.info/questions/index.html.

Later this month, i-Base will produce the first issue of a new electronic publication called ARVs4IDUs. This will be a quarterly summary of research relating to injecting drug users and HIV, with the first issue available for the IAS conference in Sydney in July.

HTB readers who currently receive HTB by email will receive this automatically as a supplement to the next issue of HTB. Print readers will need to subscribe for this new service online: http://www.i-base.info/forms/esub.php.

2007-06-10
IB070806-01

©2007. I-BASE HIV Treatment Bulletin. Permission to reproduce courtesy of HIV i-Base, Third Floor East, Thrale House, 44-46 Southwark Street, London SE1 1UN - T: +44 (0) 20 7407 8488 F: +44 (0) 20 7407 8489

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2007. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2007. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.